VEDOLIZUMAB AS FIRST-LINE BIOLOGICAL THERAPY IN ELDERLY PATIENTS AND THOSE WITH CONTRAINDICATIONS FOR ANTI-TNF THERAPY: A REAL-WORLD, NATIONWIDE COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES

Mohamed Attauabi  ¹     Camilla Höglund  ²     Janne Fassov  ³     Kenneth Bo Pedersen  ⁴     Heidi Bansholm Hansen  ⁵     Signe Wildt  ⁶     Michael Dam Jensen  ⁷     Anders Neumann  ⁸     Cecilie Lind  ⁸     Henrik Albæk Jacobsen  ⁹     Ana-Maria Popa  ¹⁰     jens kjeldsen  ¹¹     Natalia Pedersen  ¹²     akbar molazahi  ¹³     Kent Haderslev  ¹⁴     Claus Aalykke  ¹⁴     Torben Knudsen  ¹⁴     Wojciech Cebula  ¹⁴     Pia Munkholm  ¹⁴     Flemming Bendtsen  ¹⁵     Jakob Benedict Seidelin  ¹⁵     Johan Burisch  ^15    
1 Herlev Hospital, Herlev, Denmark
² OUH Svendborg Hospital, Svendborg, Denmark
³ Aarhus University Hospital, Aarhus, Denmark
⁴ Hospital of South West Denmark, Esbjerg, Denmark
⁵ North Zealand University Hospital, Frederikssund, Denmark
⁶ Zealand University Hospital, Koege, Denmark
⁷ Lillebaelt Hospital, Vejle, Denmark
⁸ Regional Hospital Viborg, Viborg, Denmark
⁹ Aalborg University Hospital, Aalborg, Denmark
¹⁰ Nykoebing Falster Hospital, Nykoebing Falster, Denmark
¹¹ OUH Odense University Hospital, Odense, Denmark
¹² Slagelse Hospital, Slagelse, Denmark
¹³ Holbaek Hospital, Holbaek, Denmark
¹⁴ Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
¹⁵ Copenhagen University Hospital, Hvidovre, Denmark

Topic
IBD

Session
IBD: Clinical trials poster II

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)